MASH is rapidly emerging as one of the most common causes of chronic liver disease worldwide, yet its economic impact has often been underestimated.
The Global NASH/MASH Council (GNC) recently conducted an in-depth analysis of the future burden of MASH across nine countries, including the U.S., Germany, France, UK, Italy, Spain, Japan, Brazil, and Saudi Arabia, projecting clinical, humanistic, and economic trends through 2040. The findings are striking. MASH cases and the associated healthcare costs are projected to rise sharply in every country studied. Beyond direct medical expenses, the disease also drives growing productivity losses and declines in quality of life.
As obesity and type 2 diabetes continue to rise, MASH is no longer just a liver disease, it is a global health and economic crisis in the making. The message for clinicians, policymakers, and health systems is clear: addressing MASH will require urgent, coordinated action across sectors. The time to act is now - to protect patients, reduce costs, and improve lives
